Introduction

Pressurised metered dose inhalers (pMDIs) are effective drug delivery devices prescribed in obstructive airway diseases due to their convenience, portability, ease of enabling multiple doses in a single formulation, and storage in any orientation. For the management of asthma, the fixed-dose combination of a long-acting β₂-agonist (LABA) and an inhaled corticosteroid (ICS) has been recommended by Global Initiative for Asthma guideline as a preferred treatment option for patients who are uncontrolled with only ICS doses. One of the available LABA/ICS combinations is the formoterol/budesonide (FB).

Areas covered

This article systematically reviews the efficacy and safety of the FB pMDI compared with the FB dry powder inhaler (DPI), individual mono-components (formoterol and budesonide) or salmeterol/fluticasone (SF) combination in the treatment of asthma among paediatric and adult patients. PubMed was searched with the string: ‘‘((Budesonide) AND Formoterol) AND ((((pMDI) OR MDI) OR Pressurised Metered-dose inhaler) OR Metered-dose inhaler)’’, in ALL fields. Screening of all the articles was done till February 2020. We have included 24 articles from the total of 142 hits received.

Conclusions

The FB pMDI is efficacious for the long-term management of asthma in patients 6 years of age and above. It has been shown to improve lung function and asthma control, and to reduce daytime and night-time symptoms, the number of rescue medication doses and asthma exacerbations. It also showed rapid onset of bronchodilatory effect with a dose–response relationship that allows patients to utilise it as a Single Maintenance And Reliever Therapy (SMART) regimen.

中文翻译：

---

比较福莫特罗/布地奈德pMDI与单组分和其他LABA / ICS在哮喘患者中的疗效和安全性。

介绍

加压定量吸入器（pMDI）是一种在阻塞性气道疾病中开具的有效药物输送装置，因为它们的方便性，便携性，易于在单一制剂中进行多次给药以及可以任何方向存储。用于治疗哮喘的管理，长效β固定剂量组合₂激动剂（LABA）和吸入皮质类固醇（ICS）已建议通过全球哮喘准则如谁是不受控制具有用于患者的优选的治疗选择仅ICS剂量。可用的LABA / ICS组合之一是福莫特罗/布地奈德（FB）。

覆盖区域

本文系统地回顾了FB pMDI与FB干粉吸入器（DPI），单个单组分（福莫特罗和布地奈德）或沙美特罗/氟替卡松（SF）组合治疗小儿和成年患者哮喘的疗效和安全性。在所有字段中用以下字符串搜索PubMed：``（（布地奈德）AND福莫特罗）AND（（（（（pMDI）OR MDI）OR加压计量吸入器）OR计量吸入器）''。筛选所有文章的工作截止到2020年2月。我们从收到的142次点击中包括了24篇文章。

结论

FB pMDI可有效治疗6岁及以上的哮喘患者。它已被证明可以改善肺功能和控制哮喘，并减少白天和夜间的症状，急救药物的剂量和哮喘的发作。它还显示了支气管扩张作用的快速发作，并具有剂量反应关系，使患者可以将其用作单一维持和缓解疗法（SMART）方案。